• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington?s disease: a review of clinical trial data
【24h】

Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington?s disease: a review of clinical trial data

机译：德替四巴嗪用于迟钝的止吐肽和与亨廷顿的舞蹈病有关的舞蹈病：对临床试验数据的综述

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Huntington?s disease (HD)-associated chorea and tardive dyskinesia (TD) are hyperkinetic movement disorders that can have deleterious effects on patients? quality of life (QoL). Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of HD-associated chorea and TD. It is structurally similar to tetrabenazine, an FDA-approved compound for treatment of chorea that is widely used off-label for treatment of TD, but has deuterium modifications that improve its pharmacokinetic profile. Areas covered: Herein, the authors cover the key clinical trials with deutetrabenazine in patients with HD-associated chorea (First-HD and ARC-HD) and in patients with TD (ARM-TD, AIM-TD, and RIM-TD). Expert opinion: Deutetrabenazine demonstrates consistent efficacy across patient types regardless of underlying psychiatric illness, or through use of dopamine-receptor antagonists (DRAs), which are the primary cause of TD. The safety profile of deutetrabenazine in clinical trials is similar to that of placebo. Long-term extension studies in both HD-associated chorea and TD show consistent efficacy and safety. Deutetrabenazine will likely be an integral part of the treatment strategy for HD-associated chorea and TD. Meanwhile, its potential to treat other hyperkinetic movement disorders is still under investigation.
机译：介绍：亨廷顿氏病（HD） - 分配的舞蹈症和迟发性障碍（TD）是对患者有害影响的过基因运动障碍吗？生活质量（QOL）。乙烯库替苯嗪是一种尿布单胺转运蛋白（VMAT2）抑制剂，受美国食品和药物管理局（FDA）的批准，用于治疗HD相关的舞程和TD。它在结构上类似于四萘嗪，用于治疗孔隙的FDA批准的化合物，这些化合物被广泛用于治疗TD的抗标签，但具有改善其药代动力学曲线的氘改性。涵盖的区域：本文，作者涵盖了HD-Cossived舞蹈症（First-HD和Arc-HD）和TD（ARM-TD，AIM-TD和RIM-TD）患者患有氘临床试验。专家意见：德替四巴嗪在患者类型上表现出一致的疗效，无论潜在的精神病疾病，还是通过使用多巴胺受体拮抗剂（DRAs），这是TD的主要原因。氘试验中氘甲磺酸丁嗪的安全性谱与安慰剂相似。 HD相关的舞蹈区和TD的长期扩展研究显示了一致的功效和安全性。氘化苯嗪可能是HD相关舞程和TD治疗策略的组成部分。同时，它仍在调查其治疗其他高硫类运动障碍的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号